

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

10

Application Number

10/698,676

Filing Date

10/31/2003

First Named Inventor

Martin T. Gerber

Art Unit

3762

Examiner Name

Matthew J. Kaszajna

Attorney Docket Number

P-11666.00

RECEIVED
CENTRAL FAX CENTER**MAR 13 2006****ENCLOSURES (Check all that apply)**

Fee Transmittal Form



Fee Attached



Amendment/Reply



After Final



Affidavits/declaration(s)



Extension of Time Request



Express Abandonment Request



Information Disclosure Statement



Certified Copy of Priority Document(s)

Reply to Missing Parts/
Incomplete ApplicationReply to Missing Parts
under 37 CFR 1.52 or 1.53

Drawing(s)



Licensing-related Papers



Petition

Petition to Convert to a
Provisional Application

Power of Attorney, Revocation



Change of Correspondence Address



Terminal Disclaimer



Request for Refund



CD, Number of CD(s) _____



Landscape Table on CD



After Allowance Communication to TC

Appeal Communication to Board
of Appeals and InterferencesAppeal Communication to TC
(Appeal Notice, Brief, Reply Brief)

Proprietary Information



Status Letter

Other Enclosure(s) (please identify
below):


Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name

Medtronic, Inc.

Signature



Printed name

Anna M. Nelson

Date

March 13, 2006


Reg. No.

48,935

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature



Typed or printed name

Jodi D. Nickel

Date

March 13, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

RECEIVED
CENTRAL FAX CENTER

MAR 13 2006


PATENT
Docket No.: P-11666.00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Martin T. Gerber	Group Art Unit:	3739
Application No.:	10/698,676	Examiner:	M. Kasztejna
Filing Date:	10/31/2003	Conf. No.:	1023
Title:	Techniques for Transrectal Delivery of a Denervating Agent to the Prostate Gland		

CERTIFICATE OF MAILING OR TRANSMISSION:

I hereby certify that this correspondence is being deposited

☐ via first class mail with the United States Postal Service with sufficient postage to Mail Stop AE,
Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450; or☒ facsimile transmitted to the U.S. Patent and Trademark Office to (571)273-8300 on
March 13, 2006.
Jodi NickelMail Stop: AF
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450**RESPONSE**

This communication is in response to the Final Office Action mailed January 13, 2006.

Please amend the above-identified application as indicated on the attached pages.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.**Remarks/Arguments** begin on page 7 of this paper.